Product
Belinostat
Aliases
Beleodaq, Beleodaq®, Belinostat Injection, PXD101 (1 other aliases)
Name
Beleodaq
INN Name
Belinostat
FDA Approved
Yes
12 clinical trials
1 organization
40 indications
1 document
Indication
Peripheral T Cell LymphomaIndication
Recurrent Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromeIndication
Acute Myeloid LeukemiaIndication
cancerIndication
NeuroendocrineIndication
TumorIndication
Neuroendocrine CarcinomaIndication
Small CellIndication
Breast CancerIndication
Ovarian CancerIndication
Uveal MelanomaIndication
Adult T-cell Leukemia-LymphomaIndication
Adult T-cell Leukemia/LymphomaIndication
Urothelial CarcinomaIndication
Sarcomatoid VariantIndication
Metastatic Urothelial CarcinomaIndication
Unresectable Urothelial CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent B-Cell Non-Hodgkin LymphomaIndication
Non-Hodgkin LymphomaIndication
Recurrent T-Cell Non-Hodgkin LymphomaIndication
B-Cell Non-Hodgkin LymphomaIndication
Refractory Non-Hodgkin LymphomaIndication
Refractory T-Cell Non-Hodgkin LymphomaIndication
Primary Central ChondrosarcomaIndication
Central ChondrosarcomaIndication
Hodgkin LymphomaIndication
Mycosis FungoidesIndication
Hodgkin's LymphomaIndication
Refractory Nodal Marginal Zone LymphomaIndication
Breast cancerIndication
Glioblastoma Multiforme of BrainClinical trial
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell LymphomaStatus: Recruiting, Estimated PCD: 2030-07-01
Clinical trial
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityStatus: Not yet recruiting, Estimated PCD: 2027-07-30
Clinical trial
A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase II Study of Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-LymphomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
RESOLVE : A Phase I Trial of Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancers With Focus on Urothelial CarcinomaStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE)Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory LymphomaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PETStatus: , Estimated PCD: 2025-04-01
Clinical trial
Quantitative Magnetic Resonance Spectroscopic Imaging (MRSI) to Predict Early Response to Standard Radiation Therapy (RT)/Temozolomide (TMZ) ± Belinostat Therapy in Newly-Diagnosed Glioblastomas (GBM)Status: Active (not recruiting), Estimated PCD: 2023-08-15
Document
DailyMed Label: BeleodaqOrganization
Acrotech Biopharma Inc